“multiple-myeloma” Archives

in
Entry Author Date Location
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue 09/09/20 National
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More 07/31/20 National
Clinical Trial Diversity Isn’t Just a Moral Issue–It’s a Scientific Imperative 07/27/20 National
Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug 06/05/20 New York
From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq 05/15/20 New York
BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info 05/13/20 New York
CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas 03/24/20 San Francisco
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More 03/13/20 National
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More 03/06/20 National
Sanofi Wins FDA Nod for Combo Therapy in Multiple Myeloma 03/03/20 National
Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic 03/02/20 Boston
Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial 01/13/20 San Francisco
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More 11/22/19 National
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More 08/30/19 National
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight 08/28/19 New York
GSK’s Cancer Comeback Continues With Data for Multiple Myeloma Drug 08/23/19 National
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs 08/16/19 New York
Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More 07/05/19 National
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More 04/26/19 National
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski 03/11/19 National
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington 02/27/19 New York
FDA Staff Hammers Karyopharm Cancer Drug on Safety, Efficacy Concerns 02/22/19 Boston
AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug 02/11/19 San Francisco
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More 02/08/19 National
Aduro Biotech Slashes Staff 37%, Turns Focus to Lead Cancer Drugs 01/30/19 San Francisco
Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments 01/04/19 San Diego
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B 01/03/19 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage 12/04/18 National
Page 1 of 5 next page »